HCV Forecast: Merck, AbbVie Next-Gen Data Not Overtaking Gilead
Executive Summary
Gilead's ASTRAL study data at AASLD represent a "shock-and-awe" campaign, setting up the company for continued HCV dominance over several competitors, Wall Street analyst asserts.
You may also be interested in...
December Approvals Forecast: FDA Decisions Will Be Fast And Frequent
Another record-breaking year of approvals seems almost certain given the number of products with user fee goals before the end of 2015.
Decompensated Cirrhosis May Be Another HCV Edge For Gilead; Bristol, J&J Still In Contention
Bristol and Johnson & Johnson have not abandoned their efforts to take a relevant place in the HCV market, although J&J isn't expected to produce triple combination data until next year.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”